Condition: Hyperprolactinemia · Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
A Phase III clinical study evaluating the efficacy and safety of cabergoline tablets versus bromocriptine mesylate tablets in patients with hyperprolactinemia
This description comes directly from the study's public registry record.
lingling Li · +86-18826108784 · lilingling01@genscigroup.com
Always discuss trial participation with your own doctor first.
| Peking Union Hospital, Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07124221